BRCA2 and pancreatic neoplasm: No evidence of clinical benefit of breast screening. Consider mammography in the case of gynecomastiaAnnual screening with PSA for prostate cancer from the age of 40 years (recommended in BRCA2, and offer in BRCA1)Consider pancreatic cancer surveillance with EUS and MRI in carriers with a first-degree relative with pancreatic cancer from the age of 50 or 10 years before the youngest diagnosis in the familyConsider skin and eye examination for melanoma screening according personal/familiar risk factors